Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

Completed · Phase 2 · Has a placebo group

Conditions studied: Locally Recurrent and Metastatic Breast Cancer

In brief

This is a phase 2, randomized, placebo controlled, multi-center study to estimate the treatment effect and evaluate the safety and tolerability of AMG 386 in combination with paclitaxel and paclitaxel/bevacizumab in the treatment of subjects with Her2-negative metastatic or locally recurrent breast cancer. AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow.

Key facts

Study ID: NCT00511459
Run by: Amgen
People needed: 228
Starts: 2007-07-01
Expected to finish: 2014-05-01
Last updated by the study team: 2015-10-29

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

Subjects must have histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent.
Measurable or non-measurable disease per modified RECIST guidelines
ECOG of 0 or 1 (within 14 days prior to randomization)
Adequate organ and hematological function as evidenced by the following laboratory studies within 14 days prior to randomization:
Cardiac function, as follows:
Normal sinus rhythm (no significant ECG changes)
Left ventricular ejection fraction ≥ LLN, as determined by echocardiogram or MUGA scan, according to institutional standards within 28 days prior to randomization

You may not qualify if…

Inflammatory Breast Cancer
Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 peripheral neuropathy > grade 1 at randomization
History of arterial or venous thrombosis, including transient ischemic attack (TIA), within 1 year prior to randomization
Adjuvant or neoadjuvant taxane treatment within 12 months of randomization. Any other adjuvant chemotherapy regimen must be discontinued at least 21 days prior to randomization
Prior chemotherapy, vaccine, or biological therapy for locally recurrent or metastatic breast cancer (prior endocrine therapy is permitted)
Prior radiation therapy, radiofrequency ablation, percutaneous cryotherapy or hepatic chemoembolization on all sites of disease unless disease progression was subsequently documented 14 days prior to randomization.
Overexpression of HER-2 (gene amplification by FISH or 3+ over expression by immunohistochemistry).
Current or prior history of central nervous system metastasis
History of bleeding diathesis or clinically significant bleeding within 6 months prior to randomization
Major surgical procedure within 28 days prior to randomization
Open breast biopsy within 14 days prior to randomization
Minor surgical procedure, placement of access device, or fine needle aspiration within 7 days of first dose
Prior malignancy (other than thyroid cancer, in situ cervical cancer, or basal cell cancer of the skin, treated with curative intent and without evidence of disease for ≥ 3 years prior to randomization)
Clinically significant cardiac disease within 12 months prior to randomization, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or arrhythmias not controlled by outpatient medication
Non-healing wound, ulcer or fracture
Known hypersensitivity to paclitaxel or drugs using the vehicle cremophor
Known hypersensitivity to bacterial proteins, or any of the drugs required in this study
Known positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B surface antigen
Known active or chronic hepatitis
Uncontrolled hypertension as defined as systolic blood pressure ≥ 150 mm Hg and diastolic blood pressure ≥ 90 mm Hg. Anti-hypertensive medications are allowed if the subject is stable on their current dose at the time of randomization
Currently or previously treated with any VEGF or VEGFr inhibitor, including but not limited to, bevacizumab, SU11248 (sunitinib), PTK787 (vatalinib), AZD 2171, AEE-788, BAY 43-9006 (sorafenib) and AMG 706.
Treatment with coumarin-type anticoagulants, (other than low dose prophylaxis for central venous catheters ≤ 1mg/day) within 7 days prior to randomization
Currently or previously treated with angiopoietin inhibitors, or inhibitors of TIE-1 or TIE-2 including, but not limited to, AMG 386, XL880, XL820
Treatment with immune modulators such as cyclosporine and tacrolimus within 30 days prior to randomization
Concomitant therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators (SERMS), given for breast cancer prevention or for osteoporosis. Subjects must have discontinued these agents 28 days prior to randomization

Where it is running

Research Site — Tucson, Arizona, United States
Research Site — Hot Springs, Arkansas, United States
Research Site — Little Rock, Arkansas, United States
Research Site — Campbell, California, United States
Research Site — Los Angeles, California, United States
Research Site — Murrieta, California, United States
Research Site — Santa Maria, California, United States
Research Site — New Haven, Connecticut, United States
Research Site — Stamford, Connecticut, United States
Research Site — Orlando, Florida, United States
Research Site — Robbinsdale, Minnesota, United States
Research Site — Henderson, Nevada, United States
Research Site — Lebanon, New Hampshire, United States
Research Site — Nashua, New Hampshire, United States
Research Site — Edison, New Jersey, United States
Research Site — Mountain Lakes, New Jersey, United States
Research Site — Asheville, North Carolina, United States
Research Site — Charlotte, North Carolina, United States
Research Site — Hershey, Pennsylvania, United States
Research Site — Philadelphia, Pennsylvania, United States
Research Site — Columbia, South Carolina, United States
Research Site — Richardson, Texas, United States
Research Site — San Antonio, Texas, United States
Research Site — Sugar Land, Texas, United States
Research Site — Litchfield Park, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.